NCT00767325 - A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Abatacept

Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169

DRUG

Methotrexate

Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline

Trial Locations (21)

1036

Local Institution, Budapest

7006

Local Institution, Trondheim

28006

Local Institution, Madrid

28040

Local Institution, Madrid

28911

Local Institution, Madrid

28935

Local Institution, Madrid

37126

Local Institution, Verona

38434

Local Institution, Échirolles

53100

Local Institution, Siena

56126

Local Institution, Pisa

60035

Local Institution, Jesi (Ancona)

76230

Local Institution, Bois-Guillaume

80639

Local Institution, München

92104

Local Institution, Boulogne

DK-2600

Local Institution, Glostrup Municipality

06202

Local Institution, Nice

00161

Local Institution, Roma

00168

Local Institution, Roma

N0319

Local Institution, Oslo

08006

Local Institution, Barcelona

LS7 4SA

Local Institution, Leeds